Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5901) 5901
Newsletter (258) 258
Newspaper Article (80) 80
Book Chapter (33) 33
Transcript (11) 11
Report (9) 9
Dissertation (4) 4
Magazine Article (4) 4
Conference Proceeding (2) 2
Publication (2) 2
Book / eBook (1) 1
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (4773) 4773
life sciences & biomedicine (4477) 4477
anthracyclines (4459) 4459
humans (4359) 4359
female (3138) 3138
cancer (2989) 2989
chemotherapy (2730) 2730
oncology (2643) 2643
middle aged (2046) 2046
adult (1857) 1857
male (1798) 1798
aged (1664) 1664
breast cancer (1426) 1426
care and treatment (1301) 1301
anthracyclines - adverse effects (1273) 1273
breast neoplasms - drug therapy (1267) 1267
doxorubicin (1235) 1235
antineoplastic combined chemotherapy protocols - therapeutic use (1231) 1231
biological and medical sciences (1105) 1105
medical sciences (1088) 1088
treatment outcome (1058) 1058
analysis (1049) 1049
research (1019) 1019
anthracycline (991) 991
antineoplastic combined chemotherapy protocols - adverse effects (990) 990
medicine & public health (977) 977
tumors (949) 949
animals (940) 940
doxorubicin - adverse effects (865) 865
antineoplastic agents - adverse effects (856) 856
doxorubicin - administration & dosage (819) 819
cardiotoxicity (776) 776
pharmacology & pharmacy (742) 742
hematology (733) 733
antibiotics, antineoplastic - adverse effects (730) 730
health aspects (704) 704
risk factors (672) 672
anthracyclines - therapeutic use (614) 614
breast neoplasms - pathology (611) 611
cyclophosphamide (605) 605
adolescent (598) 598
anthracyclines - administration & dosage (590) 590
pharmacology. drug treatments (580) 580
neoplasms - drug therapy (579) 579
antineoplastic agents - therapeutic use (560) 560
oncology, experimental (560) 560
drug therapy (554) 554
cancer therapies (552) 552
clinical trials (549) 549
metastasis (524) 524
retrospective studies (521) 521
antineoplastic agents (516) 516
disease-free survival (511) 511
toxicity (508) 508
child (502) 502
drugs (486) 486
prognosis (466) 466
patients (457) 457
cardiovascular system & cardiology (454) 454
aged, 80 and over (450) 450
antineoplastic combined chemotherapy protocols - administration & dosage (440) 440
cardiac & cardiovascular systems (440) 440
young adult (428) 428
hematology, oncology and palliative medicine (407) 407
doxorubicin - therapeutic use (402) 402
heart diseases - chemically induced (402) 402
apoptosis (401) 401
heart failure (399) 399
neoplasm staging (397) 397
trastuzumab (392) 392
antibiotics, antineoplastic - administration & dosage (380) 380
heart (378) 378
medical research (376) 376
dose-response relationship, drug (375) 375
mice (372) 372
follow-up studies (370) 370
cyclophosphamide - administration & dosage (361) 361
drug administration schedule (351) 351
drug delivery systems (340) 340
prospective studies (338) 338
time factors (332) 332
doxorubicin - pharmacology (330) 330
antibiotics, antineoplastic - therapeutic use (325) 325
echocardiography (324) 324
cancer patients (323) 323
cardiomyopathy (322) 322
antineoplastic agents - administration & dosage (320) 320
survival rate (317) 317
cancer research (312) 312
cell line, tumor (312) 312
heart - drug effects (310) 310
pharmacology/toxicology (305) 305
cardiology (304) 304
survival analysis (304) 304
taxoids - administration & dosage (297) 297
leukemia (292) 292
heart diseases (285) 285
medical colleges (281) 281
complications and side effects (280) 280
lymphomas (280) 280
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6199) 6199
Japanese (40) 40
French (32) 32
Russian (22) 22
Italian (18) 18
German (15) 15
Chinese (14) 14
Portuguese (13) 13
Czech (11) 11
Polish (7) 7
Spanish (6) 6
Danish (4) 4
Norwegian (4) 4
Slovak (4) 4
Dutch (2) 2
Finnish (2) 2
Hungarian (2) 2
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Doxorubicin pathways: pharmacodynamics and adverse effects
by Thorn, Caroline F and Oshiro, Connie and Marsh, Sharon and Hernandez-Boussard, Tina and McLeod, Howard and Klein, Teri E and Altman, Russ B
Pharmacogenetics and genomics, ISSN 1744-6872, 07/2011, Volume 21, Issue 7, pp. 440 - 446
ABCC1 | ABCC2 | NCF4 | CYBA | cardiotoxicity | pharmacogenomics | PharmGKBpathways | CAT | RAC2 | anthracyclines | doxorubicin | drug resistance | CBR3 | Pharmacology & Pharmacy | Genetics & Heredity | Life Sciences & Biomedicine | Biotechnology & Applied Microbiology | Science & Technology | Biological and medical sciences | Medical sciences | General pharmacology | Pharmacology. Drug treatments | Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions | Pharmacogenetics | Phenotype | Antibiotics, Antineoplastic - pharmacology | Intercalating Agents - adverse effects | Humans | Antibiotics, Antineoplastic - adverse effects | Drug Resistance, Neoplasm | Intercalating Agents - pharmacology | Doxorubicin - adverse effects | Doxorubicin - pharmacology | Polymorphism, Genetic | Index Medicus | PharmGKB pathways
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial
by Pritchard-Jones, Kathy, Prof and Bergeron, Christophe, MD and de Camargo, Beatriz, MD and van den Heuvel-Eibrink, Marry M, MD and Acha, Tomas, MD and Godzinski, Jan, MD and Oldenburger, Foppe, MD and Boccon-Gibod, Liliane, MD and Leuschner, Ivo, Prof and Vujanic, Gordan, Prof and Sandstedt, Bengt, MD and de Kraker, Jan, MD and van Tinteren, Harm, PhD and Graf, Norbert, MD and SIOP Renal Tumours Study Group and SIOP Renal Tumours Study Grp
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 386, Issue 9999, pp. 1156 - 1164
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Wilms Tumor - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Kidney Neoplasms - surgery | Nephrectomy | Chemotherapy, Adjuvant - adverse effects | Dactinomycin - adverse effects | Vincristine - administration & dosage | Female | Child | Doxorubicin - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Dactinomycin - administration & dosage | Wilms Tumor - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Neoadjuvant Therapy - adverse effects | Neoadjuvant Therapy - methods | Adolescent | Vincristine - adverse effects | Kidney Neoplasms - pathology | Kidney Neoplasms - drug therapy | Neoplasm Staging | Doxorubicin - adverse effects | Wilms Tumor - surgery | Care and treatment | Chemotherapy | Anthracyclines | Children | Health aspects | Tumors | Cancer | Histology | Biopsy | Medical prognosis | Clinical outcomes | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy
by Pivot, X and Marmé, F and Koenigsberg, R and Guo, M and Berrak, E and Wolfer, A
Annals of oncology, ISSN 0923-7534, 08/2016, Volume 27, Issue 8, pp. 1525 - 1531
clinical trial | triple-negative breast cancer | pooled analysis | metastatic breast cancer | eribulin | survival | Clinical trial | Metastatic breast cancer | Eribulin | Pooled analysis | Survival | Triple-negative breast cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Anthracyclines - adverse effects | Adjuvants, Pharmaceutic | Receptor, ErbB-2 - genetics | Humans | Antineoplastic Agents - therapeutic use | Furans - adverse effects | Triple Negative Breast Neoplasms - drug therapy | Furans - therapeutic use | Randomized Controlled Trials as Topic | Disease-Free Survival | Taxoids - administration & dosage | Clinical Trials, Phase III as Topic | Neoplasm Metastasis | Triple Negative Breast Neoplasms - genetics | Antineoplastic Agents - adverse effects | Triple Negative Breast Neoplasms - pathology | Bridged-Ring Compounds - adverse effects | Female | Ketones - therapeutic use | Receptor, ErbB-2 - antagonists & inhibitors | Anthracyclines - therapeutic use | Bridged-Ring Compounds - administration & dosage | Ketones - adverse effects | Taxoids - adverse effects | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Chemical Cardiomyopathies: The Negative Effects of Medications and Nonprescribed Drugs on the Heart
by Figueredo, Vincent M., MD, FACC, FAHA, FASE
The American journal of medicine, ISSN 0002-9343, 2011, Volume 124, Issue 6, pp. 480 - 488
Internal Medicine | Ecstasy | Ma huang | Anabolic steroid | Cardiomyopathy | Chloroquine | Methylenedioxymethamphetamine | Alcohol | Clozapine | Cobalt | Doxorubicin | Amphetamine | Anthracycline | Cocaine | Ephedra | Methylphenidate | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiology. Vascular system | Heart | Biological and medical sciences | Myocarditis. Cardiomyopathies | General aspects | Medical sciences | Anthracyclines - adverse effects | Heart - physiopathology | Humans | Anabolic Agents - adverse effects | Amphetamine - adverse effects | Methylphenidate - adverse effects | Chloroquine - adverse effects | Prescription Drugs - adverse effects | Ephedra - adverse effects | Cardiomyopathies - physiopathology | Antineoplastic Agents - adverse effects | Cardiomyopathies - mortality | Ethanol - adverse effects | Heart - drug effects | Nonprescription Drugs - adverse effects | Testosterone - adverse effects | Clozapine - adverse effects | Cocaine - adverse effects | Doxorubicin - adverse effects | Cardiomyopathies - chemically induced | Side effects | Chemical compounds | Medical treatment | Nonprescription drugs | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Redox nanoparticle therapeutics to cancer — increase in therapeutic effect of doxorubicin, suppressing its adverse effect
by Yoshitomi, Toru and Ozaki, Yuki and Thangavel, Sindhu and Nagasaki, Yukio
Journal of controlled release, ISSN 0168-3659, 11/2013, Volume 172, Issue 1, pp. 137 - 143
Reactive oxygen species | Transcriptional factor | Cancer chemotherapy | Doxorubicin | Nitroxide radical | pH-responsive polymeric micelle | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Free Radical Scavengers - pharmacology | Neoplasms - metabolism | Doxorubicin - therapeutic use | Reactive Oxygen Species - metabolism | Antibiotics, Antineoplastic - pharmacology | Nanoparticles - chemistry | Humans | NF-kappa B - immunology | Antibiotics, Antineoplastic - adverse effects | Delayed-Action Preparations - chemistry | Inflammation - drug therapy | Free Radical Scavengers - therapeutic use | Nitrogen Oxides - therapeutic use | Oxidation-Reduction | Free Radical Scavengers - administration & dosage | Nitrogen Oxides - administration & dosage | Inflammation - immunology | Neoplasms - drug therapy | Drug Synergism | Animals | Antibiotics, Antineoplastic - therapeutic use | Neoplasms - immunology | Nitrogen Oxides - pharmacology | Mice | Mice, Inbred BALB C | Doxorubicin - adverse effects | Doxorubicin - pharmacology | Complications and side effects | Anthracyclines | Chemotherapy | Cancer | Creatine kinase | College graduates | Creatine | Index Medicus | Adjuvants
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
by Swain, S M and Ewer, M S and Viale, G and Delaloge, S and Ferrero, J -M and Verrill, M and Colomer, R and Vieira, C and Werner, T L and Douthwaite, H and Bradley, D and Waldron-Lynch, M and Kiermaier, A and Eng-Wong, J and Dang, C and BERENICE Study Grp and BERENICE Study Group
Annals of oncology, ISSN 0923-7534, 03/2018, Volume 29, Issue 3, pp. 646 - 653
Neoadjuvant | Pertuzumab | Early breast cancer | Trastuzumab | Cardiac safety | Life Sciences & Biomedicine | Oncology | Science & Technology | Anthracyclines - adverse effects | Cyclophosphamide - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cardiotoxicity - epidemiology | Cardiotoxicity - etiology | Cyclophosphamide - adverse effects | Incidence | Anthracyclines - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Chemotherapy, Adjuvant - adverse effects | Adult | Female | Paclitaxel - administration & dosage | Taxoids - adverse effects | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Paclitaxel - adverse effects | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | Chemotherapy, Adjuvant - methods | Neoadjuvant Therapy - adverse effects | Neoadjuvant Therapy - methods | Aged | Doxorubicin - adverse effects | Index Medicus | trastuzumab | early breast cancer | neoadjuvant | Editor's Choice | pertuzumab | Original | cardiac safety
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer
by Zaheed, Milita and Wilcken, Nicholas and Willson, Melina L and O'Connell, Dianne L and Goodwin, Annabel and Goodwin, Annabel
Cochrane library, ISSN 1469-493X, 02/2019, Volume 2019, Issue 2, pp. CD012873 - CD012873
Anthracyclines | Nervous System | Neoadjuvant | Breast Neoplasms | Doxorubicin | Taxoids | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Chemotherapy, Adjuvant | Epirubicin | Fluorouracil | Neutropenia | Drug Administration Schedule | Docetaxel | Antineoplastic Agents | Antibiotics, Antineoplastic | Randomized Controlled Trials as Topic | Cyclophosphamide | Chemotherapy | Quality of Life | Breast | Disease‐Free Survival | Medicine General & Introductory Medical Sciences | Early breast cancer | Cancer | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Anthracyclines - adverse effects | Cyclophosphamide - administration & dosage | Docetaxel - adverse effects | Humans | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Agents - administration & dosage | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Docetaxel - administration & dosage | Anthracyclines - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Female | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Taxoids - adverse effects | Doxorubicin - administration & dosage | Paclitaxel - adverse effects | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Taxoids - administration & dosage | Nervous System - drug effects | Breast Neoplasms - pathology | Breast Neoplasms - mortality | Doxorubicin - adverse effects | Epirubicin - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
by Navari, Rudolph M and Nagy, Cindy K and Gray, Sarah E
Supportive care in cancer, ISSN 0941-4355, 6/2013, Volume 21, Issue 6, pp. 1655 - 1663
Breakthrough nausea and emesis | Pain Medicine | Chemotherapy | Nursing | Rehabilitation Medicine | Olanzapine | Medicine & Public Health | Oncology | Metoclopramide | Nursing Management/Nursing Research | Health Care Sciences & Services | Rehabilitation | Life Sciences & Biomedicine | Science & Technology | Cyclophosphamide - administration & dosage | Isoquinolines - adverse effects | Nausea - chemically induced | Humans | Middle Aged | Antiemetics - administration & dosage | Dexamethasone - adverse effects | Male | Antineoplastic Agents - administration & dosage | Cyclophosphamide - adverse effects | Quinuclidines - administration & dosage | Cisplatin - administration & dosage | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Antiemetics - adverse effects | Female | Nausea - drug therapy | Vomiting - prevention & control | Quinuclidines - adverse effects | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Morpholines - administration & dosage | Metoclopramide - administration & dosage | Vomiting - drug therapy | Neoplasms - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Metoclopramide - adverse effects | Cisplatin - adverse effects | Benzodiazepines - administration & dosage | Aged | Benzodiazepines - adverse effects | Isoquinolines - administration & dosage | Doxorubicin - adverse effects | Care and treatment | Cyclophosphamide | Anthracyclines | Dexamethasone | Nausea | Cancer | Side effects | Drug therapy | Vomiting | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
by Younes, Anas, Prof and Thieblemont, Catherine, Prof and Morschhauser, Franck, Prof and Flinn, Ian, MD and Friedberg, Jonathan W, Prof and Amorim, Sandy, MD and Hivert, Benedicte, MD and Westin, Jason, MD and Vermeulen, Jessica, MD and Bandyopadhyay, Nibedita, PhD and de Vries, Ronald, MSc and Balasubramanian, Sriram, PhD and Hellemans, Peter, MD and Smit, Johan W, PhD and Fourneau, Nele and Oki, Yasuhiro, MD
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1019 - 1026
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Non-Randomized Controlled Trials as Topic | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Pyrazoles - adverse effects | Severity of Illness Index | Antigens, CD20 - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Rituximab | Survival Rate | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Antigens, CD20 - drug effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, Non-Hodgkin - diagnosis | Care and treatment | Anthracyclines | Cyclophosphamide | Prednisone | Corticosteroids | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights